[10-Q] PJT Partners Inc. Quarterly Earnings Report
Instil Bio (TIL) filed an 8-K (Item 8.01) reporting partner ImmuneOnco’s interim data from a Phase 2 open-label study of bispecific antibody IMM2510/AXN-2510 plus chemotherapy in first-line advanced non-small-cell lung cancer (NSCLC) patients in China.
By 1 Jul 2025, 33 patients had received 10 mg/kg; 21 were efficacy-evaluable. The overall partial response rate (PRR) was 62 %, with a pronounced signal in squamous NSCLC (80 %, 8/10) versus non-squamous (46 %, 5/11). Most patients had undergone only a single tumor assessment at the data cut-off, limiting durability insight.
Safety appeared acceptable: no dose-limiting toxicities, no treatment-related deaths or dose reductions, and just one discontinuation. Grade ≥3 treatment-related adverse events were mainly hematologic and infrequent; VEGF-linked and immune events were uncommon and generally low-grade.
The dataset will be presented at a future medical meeting. Though preliminary and based on a small cohort, the efficacy signal and tolerability profile are encouraging for ‘2510’s continued development and could strengthen Instil’s oncology pipeline prospects.
Instil Bio (TIL) ha presentato un modulo 8-K (Voce 8.01) riportando i dati preliminari del partner ImmuneOnco da uno studio di Fase 2 in aperto sull’anticorpo bispecifico IMM2510/AXN-2510 in combinazione con chemioterapia nei pazienti cinesi con carcinoma polmonare non a piccole cellule (NSCLC) in fase avanzata, in prima linea.
Al 1° luglio 2025, 33 pazienti avevano ricevuto 10 mg/kg; 21 erano valutabili per efficacia. Il tasso complessivo di risposta parziale (PRR) è stato del 62%, con un segnale più marcato nel NSCLC squamoso (80%, 8/10) rispetto al non squamoso (46%, 5/11). La maggior parte dei pazienti aveva effettuato una sola valutazione tumorale al momento del cut-off dati, limitando la comprensione della durata della risposta.
La sicurezza è risultata accettabile: nessuna tossicità dose-limitante, nessun decesso correlato al trattamento o riduzione di dose, e solo una sospensione. Gli eventi avversi correlati al trattamento di grado ≥3 erano principalmente ematologici e rari; gli eventi legati a VEGF e immunitari erano infrequenti e generalmente di basso grado.
Il dataset sarà presentato in un prossimo congresso medico. Sebbene preliminari e basati su una coorte ridotta, il segnale di efficacia e il profilo di tollerabilità sono incoraggianti per il proseguimento dello sviluppo di ‘2510’ e potrebbero rafforzare le prospettive della pipeline oncologica di Instil.
Instil Bio (TIL) presentó un formulario 8-K (Punto 8.01) informando sobre los datos provisionales de su socio ImmuneOnco, provenientes de un estudio abierto de fase 2 con el anticuerpo bispecífico IMM2510/AXN-2510 combinado con quimioterapia en pacientes chinos con cáncer de pulmón no microcítico (NSCLC) avanzado en primera línea.
Al 1 de julio de 2025, 33 pacientes habían recibido 10 mg/kg; 21 fueron evaluables para eficacia. La tasa global de respuesta parcial (PRR) fue del 62%, con una señal pronunciada en NSCLC escamoso (80%, 8/10) frente a no escamoso (46%, 5/11). La mayoría de los pacientes solo habían tenido una evaluación tumoral al momento del corte de datos, limitando el conocimiento sobre la durabilidad de la respuesta.
La seguridad pareció aceptable: sin toxicidades limitantes de dosis, sin muertes relacionadas con el tratamiento ni reducciones de dosis, y solo una discontinuación. Los eventos adversos relacionados con el tratamiento de grado ≥3 fueron principalmente hematológicos e infrecuentes; los eventos relacionados con VEGF y los inmunitarios fueron poco comunes y generalmente de bajo grado.
El conjunto de datos se presentará en una futura reunión médica. Aunque preliminares y basados en una cohorte pequeña, la señal de eficacia y el perfil de tolerabilidad son alentadores para el desarrollo continuo de ‘2510’ y podrían fortalecer las perspectivas de la cartera oncológica de Instil.
Instil Bio (TIL)는 8-K 보고서(Item 8.01)를 제출하여 파트너인 ImmuneOnco의 중국 내 1차 치료를 받는 진행성 비소세포폐암(NSCLC) 환자 대상 2상 공개 시험에서 이중특이성 항체 IMM2510/AXN-2510과 화학요법 병용의 중간 데이터를 보고했습니다.
2025년 7월 1일까지 33명의 환자가 10 mg/kg을 투여받았으며; 21명은 효능 평가 대상이었습니다. 전체 부분 반응률(PRR)은 62%였으며, 편평세포 NSCLC에서는 80%(8/10), 비편평세포에서는 46%(5/11)로 뚜렷한 차이를 보였습니다. 대부분 환자는 데이터 컷오프 시점에 단 한 차례 종양 평가만 받아 반응 지속성에 대한 정보는 제한적입니다.
안전성은 허용 가능한 수준으로 보였습니다: 용량 제한 독성 없음, 치료 관련 사망이나 용량 감량 없음, 중단은 단 한 건이었습니다. 3등급 이상 치료 관련 이상반응은 주로 혈액학적이며 드물었고, VEGF 관련 및 면역 관련 이상반응은 드물고 대체로 경증이었습니다.
이 데이터는 추후 학술대회에서 발표될 예정입니다. 비록 소규모 코호트를 기반으로 한 예비 데이터이지만, 효능 신호와 내약성 프로필은 ‘2510’의 개발 지속에 긍정적인 신호이며 Instil의 종양학 파이프라인 전망을 강화할 수 있습니다.
Instil Bio (TIL) a déposé un rapport 8-K (point 8.01) rapportant les données intermédiaires de son partenaire ImmuneOnco issues d'une étude de phase 2 en ouvert portant sur l'anticorps bispécifique IMM2510/AXN-2510 en association avec une chimiothérapie chez des patients chinois atteints d'un cancer du poumon non à petites cellules (NSCLC) avancé en première ligne.
Au 1er juillet 2025, 33 patients avaient reçu 10 mg/kg ; 21 étaient évaluables pour l'efficacité. Le taux global de réponse partielle (PRR) était de 62 %, avec un signal marqué dans le NSCLC épidermoïde (80 %, 8/10) contre non épidermoïde (46 %, 5/11). La plupart des patients n'avaient effectué qu'une seule évaluation tumorale à la coupure des données, limitant ainsi la compréhension de la durabilité de la réponse.
La sécurité semblait acceptable : aucune toxicité limitant la dose, aucun décès lié au traitement ni réduction de dose, et une seule interruption. Les événements indésirables liés au traitement de grade ≥3 étaient principalement hématologiques et rares ; les événements liés au VEGF et immunitaires étaient peu fréquents et généralement de faible intensité.
Les données seront présentées lors d'une prochaine réunion médicale. Bien que préliminaires et basées sur une petite cohorte, le signal d'efficacité et le profil de tolérance sont encourageants pour le développement continu de ‘2510’ et pourraient renforcer les perspectives du pipeline oncologique d'Instil.
Instil Bio (TIL) reichte einen 8-K Bericht (Punkt 8.01) ein, in dem Partner ImmuneOnco Zwischendaten aus einer Phase-2-Studie mit dem bispezifischen Antikörper IMM2510/AXN-2510 plus Chemotherapie bei Patienten mit fortgeschrittenem nicht-kleinzelligem Lungenkrebs (NSCLC) in China vorstellte.
Bis zum 1. Juli 2025 hatten 33 Patienten 10 mg/kg erhalten; 21 waren für die Wirksamkeit auswertbar. Die Gesamt-Teilansprechrate (PRR) lag bei 62%, mit einem ausgeprägten Signal bei plattenepithelialem NSCLC (80 %, 8/10) gegenüber nicht-plattenepithelialem (46 %, 5/11). Die meisten Patienten hatten zum Datenstichtag nur eine Tumorbewertung, was die Einschätzung der Dauerhaftigkeit einschränkt.
Die Sicherheit erschien akzeptabel: keine dosislimitierenden Toxizitäten, keine behandlungsbedingten Todesfälle oder Dosisreduktionen, und nur eine Abbruchrate. Grad ≥3 behandlungsbedingte Nebenwirkungen waren hauptsächlich hämatologisch und selten; VEGF-assoziierte und immunologische Ereignisse waren ungewöhnlich und meist mild.
Der Datensatz wird auf einer zukünftigen medizinischen Tagung präsentiert. Obwohl vorläufig und auf eine kleine Kohorte bezogen, sind das Wirksamkeitssignal und das Verträglichkeitsprofil ermutigend für die weitere Entwicklung von ‘2510’ und könnten die Aussichten der Onkologie-Pipeline von Instil stärken.
- 62 % overall partial response rate in interim analysis, outperforming historical chemo benchmarks.
- 80 % PRR in squamous NSCLC, a subtype with high unmet need.
- No dose-limiting toxicities or treatment-related deaths; safety profile appears manageable.
- Small efficacy-evaluable cohort (n = 21) limits statistical confidence.
- Most patients had only one tumor assessment, providing little durability data.
- Results are from a single-arm study in China; lack of control arm or global data may hinder comparability.
Insights
TL;DR — Early Phase 2 data show strong PRR and clean safety; still small but directionally positive.
The 62 % PRR, especially the 80 % in squamous disease, materially exceeds typical first-line chemo benchmarks (~25-35 %). Absence of DLTs and minimal high-grade VEGF/immune toxicities suggest an attractive risk-benefit profile. However, only one scan for most subjects and lack of complete or durability data temper enthusiasm. If confirmed in larger cohorts or randomized settings, ‘2510 could challenge PD-1/VEGF combos and expand Instil’s value beyond its TIL cell-therapy focus.
TL;DR — Encouraging signal but limited sample; modest positive equity impact today.
For a development-stage company, any positive mid-phase oncology read-out can catalyze sentiment. The filing highlights differentiated efficacy in a high-incidence indication and a benign safety profile, reducing clinical risk. Yet, the data are uncontrolled, geographically limited, and lack progression-free or overall survival metrics, so valuation uplift may be constrained until more mature results or a strategic update (e.g., licensing economics) emerges.
Instil Bio (TIL) ha presentato un modulo 8-K (Voce 8.01) riportando i dati preliminari del partner ImmuneOnco da uno studio di Fase 2 in aperto sull’anticorpo bispecifico IMM2510/AXN-2510 in combinazione con chemioterapia nei pazienti cinesi con carcinoma polmonare non a piccole cellule (NSCLC) in fase avanzata, in prima linea.
Al 1° luglio 2025, 33 pazienti avevano ricevuto 10 mg/kg; 21 erano valutabili per efficacia. Il tasso complessivo di risposta parziale (PRR) è stato del 62%, con un segnale più marcato nel NSCLC squamoso (80%, 8/10) rispetto al non squamoso (46%, 5/11). La maggior parte dei pazienti aveva effettuato una sola valutazione tumorale al momento del cut-off dati, limitando la comprensione della durata della risposta.
La sicurezza è risultata accettabile: nessuna tossicità dose-limitante, nessun decesso correlato al trattamento o riduzione di dose, e solo una sospensione. Gli eventi avversi correlati al trattamento di grado ≥3 erano principalmente ematologici e rari; gli eventi legati a VEGF e immunitari erano infrequenti e generalmente di basso grado.
Il dataset sarà presentato in un prossimo congresso medico. Sebbene preliminari e basati su una coorte ridotta, il segnale di efficacia e il profilo di tollerabilità sono incoraggianti per il proseguimento dello sviluppo di ‘2510’ e potrebbero rafforzare le prospettive della pipeline oncologica di Instil.
Instil Bio (TIL) presentó un formulario 8-K (Punto 8.01) informando sobre los datos provisionales de su socio ImmuneOnco, provenientes de un estudio abierto de fase 2 con el anticuerpo bispecífico IMM2510/AXN-2510 combinado con quimioterapia en pacientes chinos con cáncer de pulmón no microcítico (NSCLC) avanzado en primera línea.
Al 1 de julio de 2025, 33 pacientes habían recibido 10 mg/kg; 21 fueron evaluables para eficacia. La tasa global de respuesta parcial (PRR) fue del 62%, con una señal pronunciada en NSCLC escamoso (80%, 8/10) frente a no escamoso (46%, 5/11). La mayoría de los pacientes solo habían tenido una evaluación tumoral al momento del corte de datos, limitando el conocimiento sobre la durabilidad de la respuesta.
La seguridad pareció aceptable: sin toxicidades limitantes de dosis, sin muertes relacionadas con el tratamiento ni reducciones de dosis, y solo una discontinuación. Los eventos adversos relacionados con el tratamiento de grado ≥3 fueron principalmente hematológicos e infrecuentes; los eventos relacionados con VEGF y los inmunitarios fueron poco comunes y generalmente de bajo grado.
El conjunto de datos se presentará en una futura reunión médica. Aunque preliminares y basados en una cohorte pequeña, la señal de eficacia y el perfil de tolerabilidad son alentadores para el desarrollo continuo de ‘2510’ y podrían fortalecer las perspectivas de la cartera oncológica de Instil.
Instil Bio (TIL)는 8-K 보고서(Item 8.01)를 제출하여 파트너인 ImmuneOnco의 중국 내 1차 치료를 받는 진행성 비소세포폐암(NSCLC) 환자 대상 2상 공개 시험에서 이중특이성 항체 IMM2510/AXN-2510과 화학요법 병용의 중간 데이터를 보고했습니다.
2025년 7월 1일까지 33명의 환자가 10 mg/kg을 투여받았으며; 21명은 효능 평가 대상이었습니다. 전체 부분 반응률(PRR)은 62%였으며, 편평세포 NSCLC에서는 80%(8/10), 비편평세포에서는 46%(5/11)로 뚜렷한 차이를 보였습니다. 대부분 환자는 데이터 컷오프 시점에 단 한 차례 종양 평가만 받아 반응 지속성에 대한 정보는 제한적입니다.
안전성은 허용 가능한 수준으로 보였습니다: 용량 제한 독성 없음, 치료 관련 사망이나 용량 감량 없음, 중단은 단 한 건이었습니다. 3등급 이상 치료 관련 이상반응은 주로 혈액학적이며 드물었고, VEGF 관련 및 면역 관련 이상반응은 드물고 대체로 경증이었습니다.
이 데이터는 추후 학술대회에서 발표될 예정입니다. 비록 소규모 코호트를 기반으로 한 예비 데이터이지만, 효능 신호와 내약성 프로필은 ‘2510’의 개발 지속에 긍정적인 신호이며 Instil의 종양학 파이프라인 전망을 강화할 수 있습니다.
Instil Bio (TIL) a déposé un rapport 8-K (point 8.01) rapportant les données intermédiaires de son partenaire ImmuneOnco issues d'une étude de phase 2 en ouvert portant sur l'anticorps bispécifique IMM2510/AXN-2510 en association avec une chimiothérapie chez des patients chinois atteints d'un cancer du poumon non à petites cellules (NSCLC) avancé en première ligne.
Au 1er juillet 2025, 33 patients avaient reçu 10 mg/kg ; 21 étaient évaluables pour l'efficacité. Le taux global de réponse partielle (PRR) était de 62 %, avec un signal marqué dans le NSCLC épidermoïde (80 %, 8/10) contre non épidermoïde (46 %, 5/11). La plupart des patients n'avaient effectué qu'une seule évaluation tumorale à la coupure des données, limitant ainsi la compréhension de la durabilité de la réponse.
La sécurité semblait acceptable : aucune toxicité limitant la dose, aucun décès lié au traitement ni réduction de dose, et une seule interruption. Les événements indésirables liés au traitement de grade ≥3 étaient principalement hématologiques et rares ; les événements liés au VEGF et immunitaires étaient peu fréquents et généralement de faible intensité.
Les données seront présentées lors d'une prochaine réunion médicale. Bien que préliminaires et basées sur une petite cohorte, le signal d'efficacité et le profil de tolérance sont encourageants pour le développement continu de ‘2510’ et pourraient renforcer les perspectives du pipeline oncologique d'Instil.
Instil Bio (TIL) reichte einen 8-K Bericht (Punkt 8.01) ein, in dem Partner ImmuneOnco Zwischendaten aus einer Phase-2-Studie mit dem bispezifischen Antikörper IMM2510/AXN-2510 plus Chemotherapie bei Patienten mit fortgeschrittenem nicht-kleinzelligem Lungenkrebs (NSCLC) in China vorstellte.
Bis zum 1. Juli 2025 hatten 33 Patienten 10 mg/kg erhalten; 21 waren für die Wirksamkeit auswertbar. Die Gesamt-Teilansprechrate (PRR) lag bei 62%, mit einem ausgeprägten Signal bei plattenepithelialem NSCLC (80 %, 8/10) gegenüber nicht-plattenepithelialem (46 %, 5/11). Die meisten Patienten hatten zum Datenstichtag nur eine Tumorbewertung, was die Einschätzung der Dauerhaftigkeit einschränkt.
Die Sicherheit erschien akzeptabel: keine dosislimitierenden Toxizitäten, keine behandlungsbedingten Todesfälle oder Dosisreduktionen, und nur eine Abbruchrate. Grad ≥3 behandlungsbedingte Nebenwirkungen waren hauptsächlich hämatologisch und selten; VEGF-assoziierte und immunologische Ereignisse waren ungewöhnlich und meist mild.
Der Datensatz wird auf einer zukünftigen medizinischen Tagung präsentiert. Obwohl vorläufig und auf eine kleine Kohorte bezogen, sind das Wirksamkeitssignal und das Verträglichkeitsprofil ermutigend für die weitere Entwicklung von ‘2510’ und könnten die Aussichten der Onkologie-Pipeline von Instil stärken.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED |
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO |
Commission File Number:
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of |
(I.R.S. Employer |
incorporation or organization) |
Identification No.) |
(Address of principal executive offices)(Zip Code)
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
☒ |
|
Accelerated Filer |
☐ |
|
Non-Accelerated Filer |
☐ |
|
Smaller Reporting Company |
|
|
|
|
Emerging Growth Company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As of July 28, 2025, there were
TABLE OF CONTENTS
|
|
Page |
||
PART I. |
|
FINANCIAL INFORMATION |
|
|
|
|
|
|
|
ITEM 1. |
|
FINANCIAL STATEMENTS |
|
4 |
|
|
|
|
|
|
|
Unaudited Condensed Consolidated Financial Statements — June 30, 2025 and 2024: |
|
|
|
|
|
|
|
|
|
Condensed Consolidated Statements of Financial Condition as of June 30, 2025 and December 31, 2024 |
|
4 |
|
|
|
|
|
|
|
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024 |
|
5 |
|
|
|
|
|
|
|
Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2025 and 2024 |
|
6 |
|
|
|
|
|
|
|
Condensed Consolidated Statements of Changes in Equity for the Three and Six Months Ended June 30, 2025 and 2024 |
|
7 |
|
|
|
|
|
|
|
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 |
|
9 |
|
|
|
|
|
|
|
Notes to Condensed Consolidated Financial Statements |
|
10 |
|
|
|
|
|
ITEM 2. |
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
|
23 |
|
|
|
|
|
ITEM 3. |
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
|
31 |
|
|
|
|
|
ITEM 4. |
|
CONTROLS AND PROCEDURES |
|
31 |
|
|
|
|
|
PART II. |
|
OTHER INFORMATION |
|
|
|
|
|
|
|
ITEM 1. |
|
LEGAL PROCEEDINGS |
|
32 |
|
|
|
|
|
ITEM 1A. |
|
RISK FACTORS |
|
32 |
|
|
|
|
|
ITEM 2. |
|
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
|
32 |
|
|
|
|
|
ITEM 3. |
|
DEFAULTS UPON SENIOR SECURITIES |
|
33 |
|
|
|
|
|
ITEM 4. |
|
MINE SAFETY DISCLOSURES |
|
33 |
|
|
|
|
|
ITEM 5. |
|
OTHER INFORMATION |
|
33 |
|
|
|
|
|
ITEM 6. |
|
EXHIBITS |
|
34 |
|
|
|
|
|
SIGNATURES |
|
35 |
PJT Partners Inc. was formed in connection with certain merger and spin-off transactions whereby the financial and strategic advisory services, restructuring and reorganization advisory services and Park Hill Group businesses of Blackstone Inc. (our “former Parent”) were combined with PJT Capital LP, a financial advisory firm founded by Paul J. Taubman in 2013 (together with its then affiliates, “PJT Capital”), and the combined business was distributed to our former Parent’s unitholders to create PJT Partners Inc., a stand-alone, independent publicly traded company. Throughout this Quarterly Report on Form 10-Q, we refer to this transaction as the “spin-off.”
PJT Partners Inc. is a holding company and its only material asset is its controlling equity interest in PJT Partners Holdings LP, a holding partnership that holds the Company’s operating subsidiaries, and certain cash and cash equivalents it may hold from time to time. As the sole general partner of PJT Partners Holdings LP, PJT Partners Inc. operates and controls all of the business and affairs and consolidates the financial results of PJT Partners Holdings LP and its operating subsidiaries.
In this Quarterly Report on Form 10-Q, unless the context requires otherwise, the words “PJT Partners Inc.” refers to PJT Partners Inc., and “PJT Partners,” the “Company,” “we,” “us” and “our” refer to PJT Partners Inc., together with its consolidated subsidiaries, including PJT Partners Holdings LP and its operating subsidiaries.
Forward-Looking Statements
Certain material presented herein contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include certain information concerning future results of operations, business strategies, acquisitions, financing plans, competitive position, potential growth opportunities, potential operating performance improvements, the effects of competition and the effects of future legislation or regulations. Forward-looking statements include all statements that are not historical facts and can be identified by the use of forward-looking terminology such as the words “believe,” “expect,” “opportunity,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “continue,” “may,” “might,” “should,” “could” or the negative of these terms or similar expressions.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance upon any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (a) changes in governmental regulations and policies; (b) cyber attacks, security vulnerabilities and internet disruptions, including breaches of data security and privacy leaks, data loss and business interruptions; (c) failures of our computer systems or communication systems, including as a result of a catastrophic event and the use of remote environments; (d) the impact of catastrophic events, including business disruptions, pandemics, reductions in employment and an increase in business failures on (1) the U.S. and the global economy and (2) our employees and our ability to provide services to our clients and respond to their needs; (e) the failure of third-party service providers to perform their functions; and (f) volatility in the political and economic environment, including as a result of inflation, changes to international trade policies, elevated interest rates, and geopolitical and military conflicts.
2
Any of these factors, as well as such other factors discussed in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the United States Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in our periodic filings with the SEC, accessible on the SEC’s website at www.sec.gov, could cause our results to differ materially from those expressed in forward-looking statements. There may be other risks and uncertainties that we are unable to predict at this time or that are not currently expected to have a material adverse effect on our business. Any such risks could cause our results to differ materially from those expressed in forward-looking statements.
Website Disclosure
We use our website (www.pjtpartners.com) as a channel of distribution of Company information. The information we post may be deemed material. Accordingly, investors should monitor the website, in addition to following our press releases, SEC filings and public conference calls and webcasts. In addition, you may automatically receive e-mail alerts and other information about PJT Partners when you enroll your e-mail address by visiting the “Investor Relations” page of our website at ir.pjtpartners.com. Although we refer to our website in this report, the contents of our website are not included or incorporated by reference into this report. All references to our website in this report are intended to be inactive textual references only.
3
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
PJT Partners Inc.
Condensed Consolidated Statements of Financial Condition (Unaudited)
(Dollars in Thousands, Except Share and Per Share Data)
|
|
June 30, |
|
|
December 31, |
|
||
Assets |
|
|
|
|
|
|
||
Cash and Cash Equivalents |
|
$ |
|
|
$ |
|
||
Investments (at fair value) |
|
|
|
|
|
|
||
Accounts Receivable (net of allowance for credit losses of $ |
|
|
|
|
|
|
||
Intangible Assets, Net |
|
|
|
|
|
|
||
Goodwill |
|
|
|
|
|
|
||
Furniture, Equipment and Leasehold Improvements, Net |
|
|
|
|
|
|
||
Operating Lease Right-of-Use Assets |
|
|
|
|
|
|
||
Other Assets |
|
|
|
|
|
|
||
Deferred Tax Asset, Net |
|
|
|
|
|
|
||
Total Assets |
|
$ |
|
|
$ |
|
||
Liabilities and Equity |
|
|
|
|
|
|
||
Accrued Compensation and Benefits |
|
$ |
|
|
$ |
|
||
Accounts Payable, Accrued Expenses and Other Liabilities |
|
|
|
|
|
|
||
Operating Lease Liabilities |
|
|
|
|
|
|
||
Amount Due Pursuant to Tax Receivable Agreement |
|
|
|
|
|
|
||
Taxes Payable |
|
|
|
|
|
|
||
Deferred Revenue |
|
|
|
|
|
|
||
Total Liabilities |
|
|
|
|
|
|
||
Commitments and Contingencies |
|
|
|
|
|
|
||
Equity |
|
|
|
|
|
|
||
Class A Common Stock, par value $ |
|
|
|
|
|
|
||
Class B Common Stock, par value $ |
|
|
— |
|
|
|
— |
|
Additional Paid-In Capital |
|
|
|
|
|
|
||
Retained Earnings |
|
|
|
|
|
|
||
Accumulated Other Comprehensive Income (Loss) |
|
|
|
|
|
( |
) |
|
Treasury Stock at Cost ( |
|
|
( |
) |
|
|
( |
) |
Total PJT Partners Inc. Equity |
|
|
|
|
|
|
||
Non-Controlling Interests |
|
|
|
|
|
|
||
Total Equity |
|
|
|
|
|
|
||
Total Liabilities and Equity |
|
$ |
|
|
$ |
|
See notes to condensed consolidated financial statements.
4
PJT Partners Inc.
Condensed Consolidated Statements of Operations (Unaudited)
(Dollars in Thousands, Except Share and Per Share Data)
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Advisory Fees |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Placement Fees |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest Income and Other |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Compensation and Benefits |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Occupancy and Related |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Travel and Related |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Professional Fees |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Communications and Information Services |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Depreciation and Amortization |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Income Before Provision (Benefit) for Taxes |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Provision (Benefit) for Taxes |
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|||
Net Income |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net Income Attributable to |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net Income Attributable to PJT Partners Inc. |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Net Income Per Share of Class A Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Diluted |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Weighted-Average Shares of Class A Common |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Diluted |
|
|
|
|
|
|
|
|
|
|
|
|
See notes to condensed consolidated financial statements.
5
PJT Partners Inc.
Condensed Consolidated Statements of Comprehensive Income (Unaudited)
(Dollars in Thousands)
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Net Income |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Other Comprehensive Income (Loss), Net of Tax — |
|
|
|
|
|
( |
) |
|
|
|
|
|
( |
) |
||
Comprehensive Income |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Less: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Comprehensive Income Attributable to Non- |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Comprehensive Income Attributable to PJT Partners Inc. |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
See notes to condensed consolidated financial statements.
6
PJT Partners Inc.
Condensed Consolidated Statements of Changes in Equity (Unaudited)
(Dollars in Thousands, Except Share Data)
|
|
Shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
|
Class A |
|
|
Class B |
|
|
|
|
|
Class A |
|
|
Class B |
|
|
Additional |
|
|
|
|
|
Other |
|
|
|
|
|
Non- |
|
|
|
|
|||||||||||
|
|
Common |
|
|
Common |
|
|
Treasury |
|
|
Common |
|
|
Common |
|
|
Paid-In |
|
|
Retained |
|
|
Comprehensive |
|
|
Treasury |
|
|
Controlling |
|
|
|
|
|||||||||||
|
|
Stock |
|
|
Stock |
|
|
Stock |
|
|
Stock |
|
|
Stock |
|
|
Capital |
|
|
Earnings |
|
|
Income |
|
|
Stock |
|
|
Interests |
|
|
Total |
|
|||||||||||
Balance at March 31, 2025 |
|
|
|
|
|
|
|
|
( |
) |
|
$ |
|
|
$ |
— |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|
$ |
|
||||||||
Net Income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|||
Other Comprehensive Income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|||
Dividends Declared ($ |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
Tax Distributions |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Equity-Based Compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|||
Net Share Settlement |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
Deliveries of Vested Shares of |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
Change in Ownership Interest |
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
|
Treasury Stock Purchases |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
Balance at June 30, 2025 |
|
|
|
|
|
|
|
|
( |
) |
|
$ |
|
|
$ |
— |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|
$ |
|
|
|
Shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
|
Class A |
|
|
Class B |
|
|
|
|
|
Class A |
|
|
Class B |
|
|
Additional |
|
|
|
|
|
Other |
|
|
|
|
|
Non- |
|
|
|
|
|||||||||||
|
|
Common |
|
|
Common |
|
|
Treasury |
|
|
Common |
|
|
Common |
|
|
Paid-In |
|
|
Retained |
|
|
Comprehensive |
|
|
Treasury |
|
|
Controlling |
|
|
|
|
|||||||||||
|
|
Stock |
|
|
Stock |
|
|
Stock |
|
|
Stock |
|
|
Stock |
|
|
Capital |
|
|
Earnings |
|
|
Income (Loss) |
|
|
Stock |
|
|
Interests |
|
|
Total |
|
|||||||||||
Balance at December 31, 2024 |
|
|
|
|
|
|
|
|
( |
) |
|
$ |
|
|
$ |
— |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
|
$ |
|
|||||||
Net Income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|||
Other Comprehensive Income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
|
|||
Dividends Declared ($ |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
Tax Distributions |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Equity-Based Compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|||
Net Share Settlement |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
Deliveries of Vested Shares of |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
||
Change in Ownership Interest |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
||
Treasury Stock Purchases |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
Balance at June 30, 2025 |
|
|
|
|
|
|
|
|
( |
) |
|
$ |
|
|
$ |
— |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|
$ |
|
(continued)
See notes to condensed consolidated financial statements.
7
PJT Partners Inc.
Condensed Consolidated Statements of Changes in Equity (Unaudited)
(Dollars in Thousands, Except Share Data)
|
|
Shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
|
Class A |
|
|
Class B |
|
|
|
|
|
Class A |
|
|
Class B |
|
|
Additional |
|
|
|
|
|
Other |
|
|
|
|
|
Non- |
|
|
|
|
|||||||||||
|
|
Common |
|
|
Common |
|
|
Treasury |
|
|
Common |
|
|
Common |
|
|
Paid-In |
|
|
Retained |
|
|
Comprehensive |
|
|
Treasury |
|
|
Controlling |
|
|
|
|
|||||||||||
|
|
Stock |
|
|
Stock |
|
|
Stock |
|
|
Stock |
|
|
Stock |
|
|
Capital |
|
|
Earnings |
|
|
(Loss) |
|
|
Stock |
|
|
Interests |
|
|
Total |
|
|||||||||||
Balance at March 31, 2024 |
|
|
|
|
|
|
|
|
( |
) |
|
$ |
|
|
$ |
— |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
|
$ |
|
|||||||
Net Income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|||
Other Comprehensive Loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Dividends Declared ($ |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
Tax Distributions |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Equity-Based Compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|||
Net Share Settlement |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
Deliveries of Vested Shares of |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
||
Change in Ownership Interest |
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
( |
) |
|
Treasury Stock Purchases |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
Balance at June 30, 2024 |
|
|
|
|
|
|
|
|
( |
) |
|
$ |
|
|
$ |
— |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
|
$ |
|
|
|
Shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
|
Class A |
|
|
Class B |
|
|
|
|
|
Class A |
|
|
Class B |
|
|
Additional |
|
|
|
|
|
Other |
|
|
|
|
|
Non- |
|
|
|
|
|||||||||||
|
|
Common |
|
|
Common |
|
|
Treasury |
|
|
Common |
|
|
Common |
|
|
Paid-In |
|
|
Retained |
|
|
Comprehensive |
|
|
Treasury |
|
|
Controlling |
|
|
|
|
|||||||||||
|
|
Stock |
|
|
Stock |
|
|
Stock |
|
|
Stock |
|
|
Stock |
|
|
Capital |
|
|
Earnings |
|
|
(Loss) |
|
|
Stock |
|
|
Interests |
|
|
Total |
|
|||||||||||
Balance at December 31, 2023 |
|
|
|
|
|
|
|
|
( |
) |
|
$ |
|
|
$ |
— |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
|
$ |
|
|||||||
Net Income |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|||
Other Comprehensive Loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Dividends Declared ($ |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
Tax Distributions |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Equity-Based Compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|||
Net Share Settlement |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
Deliveries of Vested Shares of |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
||
Change in Ownership Interest |
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
( |
) |
|
Treasury Stock Purchases |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
Balance at June 30, 2024 |
|
|
|
|
|
|
|
|
( |
) |
|
$ |
|
|
$ |
— |
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
|
$ |
|
See notes to condensed consolidated financial statements.
8
PJT Partners Inc.
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in Thousands)
|
|
Six Months Ended June 30, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Operating Activities |
|
|
|
|
|
|
||
Net Income |
|
$ |
|
|
$ |
|
||
Adjustments to Reconcile Net Income to Net Cash Provided by |
|
|
|
|
|
|
||
Equity-Based Compensation Expense |
|
|
|
|
|
|
||
Depreciation and Amortization Expense |
|
|
|
|
|
|
||
Amortization of Operating Lease Right-of-Use Assets |
|
|
|
|
|
|
||
Provision for Credit Losses |
|
|
|
|
|
|
||
Other |
|
|
( |
) |
|
|
|
|
Cash Flows Due to Changes in Operating Assets and Liabilities |
|
|
|
|
|
|
||
Accounts Receivable |
|
|
( |
) |
|
|
( |
) |
Other Assets |
|
|
|
|
|
|
||
Accrued Compensation and Benefits |
|
|
( |
) |
|
|
( |
) |
Accounts Payable, Accrued Expenses and Other Liabilities |
|
|
|
|
|
( |
) |
|
Taxes Payable |
|
|
( |
) |
|
|
( |
) |
Deferred Revenue |
|
|
|
|
|
|
||
Net Cash Provided by Operating Activities |
|
|
|
|
|
|
||
Investing Activities |
|
|
|
|
|
|
||
Purchases of Investments |
|
|
( |
) |
|
|
( |
) |
Proceeds from Sales and Maturities of Investments |
|
|
|
|
|
|
||
Purchases of Furniture, Equipment and Leasehold Improvements |
|
|
( |
) |
|
|
( |
) |
Net Cash Used in Investing Activities |
|
|
( |
) |
|
|
( |
) |
Financing Activities |
|
|
|
|
|
|
||
Dividends |
|
|
( |
) |
|
|
( |
) |
Tax Distributions |
|
|
( |
) |
|
|
( |
) |
Employee Taxes Paid for Shares Withheld |
|
|
( |
) |
|
|
( |
) |
Cash-Settled Exchanges of Partnership Units |
|
|
( |
) |
|
|
( |
) |
Treasury Stock Purchases |
|
|
( |
) |
|
|
( |
) |
Payments Pursuant to Tax Receivable Agreement |
|
|
( |
) |
|
|
( |
) |
Net Cash Used in Financing Activities |
|
|
( |
) |
|
|
( |
) |
Effect of Exchange Rate Changes on Cash and Cash Equivalents |
|
|
|
|
|
( |
) |
|
Net Decrease in Cash and Cash Equivalents |
|
|
( |
) |
|
|
( |
) |
Cash and Cash Equivalents, Beginning of Period |
|
|
|
|
|
|
||
Cash and Cash Equivalents, End of Period |
|
$ |
|
|
$ |
|
||
Supplemental Disclosure of Cash Flows Information |
|
|
|
|
|
|
||
Payments for Income Taxes, Net of Refunds Received |
|
$ |
|
|
$ |
|
See notes to condensed consolidated financial statements.
9
PJT Partners Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)
(All Dollars Are in Thousands, Except Share and Per Share Data, Except Where Noted)
PJT Partners Inc. and its consolidated subsidiaries (the “Company” or “PJT Partners”) offer a unique portfolio of advisory and placement services designed to help clients achieve their strategic objectives.
On October 1, 2015, Blackstone Inc. (the “former Parent”) distributed on a pro rata basis to its common unitholders all of the issued and outstanding shares of Class A common stock of PJT Partners Inc. held by it. This pro rata distribution is referred to as the “Distribution.” The separation of the PJT Partners business from the former Parent and related transactions, including the Distribution, the internal reorganization that preceded the Distribution and the acquisition by PJT Partners of PJT Capital LP (together with its general partner and their respective subsidiaries, “PJT Capital”) that occurred substantially concurrently with the Distribution, is referred to as the “spin-off.”
Basis of Presentation
The Company prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the U.S. (“GAAP”) for interim financial information and the instructions to Form 10-Q. The condensed consolidated financial statements, including these notes, are unaudited and exclude some of the disclosures required in annual financial statements. Management believes it has made all necessary adjustments (consisting of only normal recurring items) so that the condensed consolidated financial statements are presented fairly and that estimates made in preparing its condensed consolidated financial statements are reasonable and prudent. The operating results presented for interim periods are not necessarily indicative of the results that may be expected for any other interim period or for the entire year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.
Intercompany transactions have been eliminated for all periods presented.
For a comprehensive disclosure of the Company’s significant accounting policies, see Note 2. “Summary of Significant Accounting Policies” in the “Notes to Consolidated Financial Statements” in “Part II. Item 8. Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.
Cash, Cash Equivalents and Investments
Cash and Cash Equivalents include (i) highly liquid money market funds, (ii) short-term interest bearing and non-interest bearing accounts, and (iii) short-term investments that are readily convertible to known amounts of cash and have original maturities of three months or less from the date of purchase. Cash and Cash Equivalents are maintained in U.S. and non-U.S. bank accounts. Also included in Cash and Cash Equivalents are amounts held in bank accounts that are subject to advance notification to withdraw, which totaled $
Treasury securities with original maturities greater than three months when purchased are classified as Investments in the Condensed Consolidated Statements of Financial Condition.
10
PJT Partners Inc.
Notes to Condensed Consolidated Financial Statements – Continued (Unaudited)
(All Dollars Are in Thousands, Except Share and Per Share Data, Except Where Noted)
Reclassifications
Certain balances on the Condensed Consolidated Statements of Operations in the prior period have been reclassified to conform to their current presentation. For the three and six months ended June 30, 2024, this resulted in a reclassification of $
Recent Accounting Developments
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2023-09, Improvement to Income Tax Disclosures ("ASU 2023-09"). ASU 2023-09 provides guidance to enhance existing income tax disclosures related to the effective tax rate reconciliation and income taxes paid. The guidance is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted. The Company is currently assessing the impact that adoption will have on its condensed consolidated financial statements.
In November 2024, the FASB issued Accounting Standards Update 2024-03, Disaggregation of Income Statement Expenses ("ASU 2024-03"). ASU 2024-03 primarily requires enhanced disclosures about certain types of expenses. The guidance is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently assessing the impact that adoption will have on its condensed consolidated financial statements.
The following table provides a disaggregation of revenues recognized from contracts with customers for the three and six months ended June 30, 2025 and 2024:
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Advisory Fees |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Placement Fees |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest Income from Placement Fees and Other |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Revenues from Contracts with Customers |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Performance Obligations
As of June 30, 2025, the aggregate amount of the transaction price allocated to performance obligations yet to be satisfied was $
The Company recognized revenue of $
Contract Balances
There were no significant impairments related to contract balances during the three and six months ended June 30, 2025 and 2024.
11
PJT Partners Inc.
Notes to Condensed Consolidated Financial Statements – Continued (Unaudited)
(All Dollars Are in Thousands, Except Share and Per Share Data, Except Where Noted)
For the six months ended June 30, 2025 and 2024, $
Changes in the allowance for credit losses consist of the following:
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Beginning Balance |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Provision for Credit Losses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Write-offs |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Recoveries |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Ending Balance |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Included in Accounts Receivable, Net is accrued interest of $
Included in Accounts Receivable, Net are long-term receivables of $
The Company does not have any long-term receivables on non-accrual status. Of receivables that originated as long-term, there were $
Intangible Assets, Net consists of the following:
|
|
June 30, |
|
|
December 31, |
|
||
Finite-Lived Intangible Assets |
|
|
|
|
|
|
||
Customer Relationships |
|
$ |
|
|
$ |
|
||
Trade Name |
|
|
|
|
|
|
||
Total Intangible Assets |
|
|
|
|
|
|
||
Accumulated Amortization |
|
|
|
|
|
|
||
Customer Relationships |
|
|
( |
) |
|
|
( |
) |
Trade Name |
|
|
( |
) |
|
|
( |
) |
Total Accumulated Amortization |
|
|
( |
) |
|
|
( |
) |
Intangible Assets, Net |
|
$ |
|
|
$ |
|
Amortization expense was $
Amortization of Intangible Assets held at June 30, 2025 is expected to be $
12
PJT Partners Inc.
Notes to Condensed Consolidated Financial Statements – Continued (Unaudited)
(All Dollars Are in Thousands, Except Share and Per Share Data, Except Where Noted)
ending December 31, 2027, 2028 and 2029. The intangible assets as of June 30, 2025 are expected to amortize over a weighted-average period of
Furniture, Equipment and Leasehold Improvements, Net consists of the following:
|
|
June 30, |
|
|
December 31, |
|
||
Leasehold Improvements |
|
$ |
|
|
$ |
|
||
Furniture and Fixtures |
|
|
|
|
|
|
||
Office Equipment |
|
|
|
|
|
|
||
Total Furniture, Equipment and Leasehold Improvements |
|
|
|
|
|
|
||
Accumulated Depreciation |
|
|
( |
) |
|
|
( |
) |
Furniture, Equipment and Leasehold Improvements, Net |
|
$ |
|
|
$ |
|
Depreciation expense was $
The following tables summarize the valuation of the Company’s investments by the fair value hierarchy:
|
|
June 30, 2025 |
|
|||||||||||||
|
|
Level I |
|
|
Level II |
|
|
Level III |
|
|
Total |
|
||||
Treasury Securities |
|
$ |
— |
|
|
$ |
|
|
$ |
— |
|
|
$ |
|
||
Money Market Funds |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
||
Total |
|
$ |
— |
|
|
$ |
|
|
$ |
— |
|
|
$ |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
December 31, 2024 |
|
|||||||||||||
|
|
Level I |
|
|
Level II |
|
|
Level III |
|
|
Total |
|
||||
Treasury Securities |
|
$ |
— |
|
|
$ |
|
|
$ |
— |
|
|
$ |
|
||
Money Market Funds |
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
||
Total |
|
$ |
— |
|
|
$ |
|
|
$ |
— |
|
|
$ |
|
Investments in Treasury securities were included in Investments at June 30, 2025 and December 31, 2024 in the Condensed Consolidated Statements of Financial Condition. Investments in money market funds were included in Cash and Cash Equivalents at June 30, 2025 and December 31, 2024 in the Condensed Consolidated Statements of Financial Condition.
The following table summarizes the Company’s tax position:
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Income Before Provision (Benefit) for Taxes |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Provision (Benefit) for Taxes |
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|||
Effective Income Tax Rate |
|
|
% |
|
|
% |
|
|
- |
% |
|
|
% |
13
PJT Partners Inc.
Notes to Condensed Consolidated Financial Statements – Continued (Unaudited)
(All Dollars Are in Thousands, Except Share and Per Share Data, Except Where Noted)
The Company’s effective tax rate differed from the U.S. federal statutory tax rate for the three and six months ended June 30, 2025 primarily due to partnership income not being subject to U.S. corporate income taxes, state and local taxes, and permanent differences related to equity-based compensation.
The Company had
On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”), which includes a broad range of tax reform provisions, was signed into law in the United States. The Company is continuing to assess the impact of OBBBA and does not expect it to have a material impact on the Company’s 2025 condensed consolidated financial statements.
Basic and diluted net income per share of PJT Partners Inc. Class A common stock for the three and six months ended June 30, 2025 and 2024 is presented below:
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net Income Attributable to Shares of Class A |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Incremental Net Income from Dilutive Securities |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net Income Attributable to Shares of Class A |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted-Average Shares of Class A Common |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted-Average Number of Incremental Shares from |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted-Average Number of Incremental Shares from |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted-Average Shares of Class A Common |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net Income Per Share of Class A Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Diluted |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Holders of common units of partnership interest in PJT Partners Holdings LP (“Partnership Units”) (other than PJT Partners Inc.) have the right, subject to the terms and conditions set forth in the partnership agreement of PJT Partners Holdings LP, as amended and restated, on a quarterly basis (subject to the terms of the exchange agreement, as amended), exchange all or part of their Partnership Units for PJT Partners Inc. Class A common stock on a one-for-one basis, subject to applicable vesting and transfer restrictions. If all Partnership Units were exchanged for PJT Partners Inc. Class A common stock, weighted-average PJT Partners Inc. Class A common stock outstanding would be
Share Repurchase Program
On February 6, 2024, the Company announced that the Board authorized a $
14
PJT Partners Inc.
Notes to Condensed Consolidated Financial Statements – Continued (Unaudited)
(All Dollars Are in Thousands, Except Share and Per Share Data, Except Where Noted)
25, 2022. As of June 30, 2025, the Company’s remaining repurchase authorization was $
During the six months ended June 30, 2025, the Company repurchased
Overview
Further information regarding the Company’s equity-based compensation awards is described in Note 10. “Equity-Based and Other Deferred Compensation” in the “Notes to Consolidated Financial Statements” in “Part II. Item 8. Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.
The following table represents equity-based compensation expense and the related income tax benefit for the three and six months ended June 30, 2025 and 2024:
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Equity-Based Compensation Expense |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Income Tax Benefit |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Restricted Stock Units
The following table summarizes activity related to unvested RSUs, including those that have fully achieved market conditions in prior periods and remain subject to service conditions, for the six months ended June 30, 2025:
|
|
Restricted Stock Units |
|
|||||
|
|
|
|
|
Weighted- |
|
||
|
|
|
|
|
Average |
|
||
|
|
|
|
|
Grant Date |
|
||
|
|
Number of |
|
|
Fair Value |
|
||
|
|
Units |
|
|
(in dollars) |
|
||
Balance, December 31, 2024 |
|
|
|
|
$ |
|
||
Granted |
|
|
|
|
|
|
||
Dividends Reinvested on RSUs |
|
|
( |
) |
|
|
|
|
Forfeited |
|
|
( |
) |
|
|
|
|
Vested |
|
|
( |
) |
|
|
|
|
Balance, June 30, 2025 |
|
|
|
|
$ |
|
As of June 30, 2025, there was $
15
PJT Partners Inc.
Notes to Condensed Consolidated Financial Statements – Continued (Unaudited)
(All Dollars Are in Thousands, Except Share and Per Share Data, Except Where Noted)
Partnership Units
The following table summarizes activity related to unvested Partnership Units, including those that have fully achieved market conditions in prior periods and remain subject to service conditions, for the six months ended June 30, 2025:
|
|
Partnership Units |
|
|||||
|
|
|
|
|
Weighted- |
|
||
|
|
|
|
|
Average |
|
||
|
|
Number of |
|
|
Grant Date |
|
||
|
|
Partnership |
|
|
Fair Value |
|
||
|
|
Units |
|
|
(in dollars) |
|
||
Balance, December 31, 2024 |
|
|
|
|
$ |
|
||
Granted |
|
|
|
|
|
|
||
Vested |
|
|
( |
) |
|
|
|
|
Balance, June 30, 2025 |
|
|
|
|
$ |
|
As of June 30, 2025, there was $
Units Expected to Vest
The following unvested units, after expected forfeitures, as of June 30, 2025, are expected to vest:
|
|
|
|
|
Weighted- |
|
||
|
|
|
|
|
Service Period |
|
||
|
|
Units |
|
|
in Years |
|
||
Restricted Stock Units |
|
|
|
|
|
|
||
Partnership Units |
|
|
|
|
|
|
||
Total Equity-Based Awards |
|
|
|
|
|
|
Deferred Cash Compensation
The Company has periodically issued deferred cash compensation in connection with annual incentive compensation as well as other hiring or retention related awards. These awards typically vest over a period of one to
16
PJT Partners Inc.
Notes to Condensed Consolidated Financial Statements – Continued (Unaudited)
(All Dollars Are in Thousands, Except Share and Per Share Data, Except Where Noted)
The components of lease expense were as follows:
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Operating Lease Cost |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Variable Lease Cost |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Sublease Income |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Total Lease Cost |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Supplemental information related to the Company’s operating leases was as follows:
|
|
Six Months Ended June 30, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Cash Paid for Amounts Included in Measurement of Lease Liabilities |
|
|
|
|
|
|
||
Operating Cash Flows from Operating Leases |
|
$ |
|
|
$ |
|
||
Right-of-Use Assets Obtained in Exchange for Operating Lease Liabilities |
|
$ |
|
|
$ |
— |
|
|
|
June 30, |
|
|
December 31, |
|
||
Weighted-Average Remaining Lease Term (in years) |
|
|
|
|
|
|
||
Weighted-Average Discount Rate |
|
|
% |
|
|
% |
The following is a maturity analysis of the annual undiscounted cash flows of the Company’s operating lease liabilities as of June 30, 2025:
Year Ending December 31, |
|
|
|
|
2025 (July 1 through December 31) |
|
$ |
|
|
2026 |
|
|
|
|
2027 |
|
|
|
|
2028 |
|
|
|
|
2029 |
|
|
|
|
Thereafter |
|
|
|
|
Total Lease Payments |
|
|
|
|
Less: Tenant Improvement Allowances |
|
|
|
|
Less: Imputed Interest |
|
|
|
|
Total |
|
$ |
|
Exchange Agreement
The Company has entered into an exchange agreement, as amended, with the limited partners of PJT Partners Holdings LP pursuant to which they (or certain permitted transferees) have the right, subject to the terms and conditions set forth in the Third Amended and Restated Limited Partnership Agreement of PJT Partners Holdings LP (the “Partnership Agreement”), on a quarterly basis, to exchange all or part of their Partnership Units. Further, pursuant to the terms in the Partnership Agreement of PJT Partners Holdings LP, the Company may also require holders of Partnership Units who are not Service Providers (as defined in the Partnership Agreement of PJT Partners Holdings LP) to exchange such Partnership Units. The Company retains the sole option to determine whether to settle the exchange in either cash or for shares of PJT Partners Inc. Class A common stock on a
17
PJT Partners Inc.
Notes to Condensed Consolidated Financial Statements – Continued (Unaudited)
(All Dollars Are in Thousands, Except Share and Per Share Data, Except Where Noted)
Further information regarding the exchange agreement is described in Note 13. “Transactions with Related Parties—Exchange Agreement” in the “Notes to Consolidated Financial Statements” in “Part II. Item 8. Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.
For the six months ended June 30, 2025 and 2024, certain holders of Partnership Units exchanged
With respect to the second quarter 2025 exchange, certain holders of Partnership Units presented the Company with
Registration Rights Agreement
The Company has entered into a registration rights agreement with the limited partners of PJT Partners Holdings LP pursuant to which the Company granted them, their affiliates and certain of their transferees the right, under certain circumstances and subject to certain restrictions, to require the Company to register under the Securities Act of 1933 shares of the Company’s Class A common stock delivered in exchange for Partnership Units. The registration rights agreement does not contain any penalties associated with failure to file or to maintain the effectiveness of a registration statement covering the shares owned by individuals covered by such agreement.
Tax Receivable Agreement
The Company has entered into a tax receivable agreement with the holders of Partnership Units (other than PJT Partners Inc.) that provides for the payment by PJT Partners Inc. to exchanging holders of Partnership Units of
Sublease
The Company has entered into a Sublease Agreement (the “Sublease”) with Dynasty Equity Partners Management, LLC (“Dynasty”) to sublease a portion of its office space to Dynasty. K. Don Cornwell, a member of the Board, is the CEO and co-founder of Dynasty. The sublease commenced on
Aircraft Lease
The Company makes available to its CEO and, on occasion by exception, to other partners, including the Company’s Named Executive Officers, personal use of a company leased aircraft when it is not being used for business purposes, for which the Company is reimbursed the cost associated with such use. Such amount is not material to the condensed consolidated financial statements.
18
PJT Partners Inc.
Notes to Condensed Consolidated Financial Statements – Continued (Unaudited)
(All Dollars Are in Thousands, Except Share and Per Share Data, Except Where Noted)
Commitments
Line of Credit
On July 29, 2024, PJT Partners Holdings LP, as borrower (the “Borrower”), entered into a syndicated revolving credit agreement (the “Credit Agreement”) and related documents with Bank of America, N.A., as the administrative agent (the “Administrative Agent”), and certain other financial institutions party thereto as lenders. The Credit Agreement provides for a revolving credit facility with aggregate principal amount of up to $
The Credit Agreement contains usual and customary affirmative and negative covenants that among other things, limit or restrict the ability of the Borrower (subject to certain qualifications and exceptions) to make certain payments and enter into certain transactions. The Borrower is required to comply with the following financial covenants (in each case, as defined in the Credit Agreement):
A breach of such covenants or any other event of default would entitle the Administrative Agent to accelerate the Borrower’s debt obligations under the Credit Agreement.
As of June 30, 2025 and December 31, 2024, there were
As of June 30, 2025 and December 31, 2024, the Company was in compliance with the debt covenants under the Credit Agreement.
Contingencies
Litigation
From time to time, the Company may be named as a defendant in legal actions relating to transactions conducted in the ordinary course of business. Some of these matters may involve claims of substantial amounts. Although there can be no assurance of the outcome of such legal actions, in the opinion of management, after consultation with external counsel, the Company believes it is not probable and/or reasonably possible that any current legal proceedings or claims would individually or in the aggregate have a material adverse effect on the condensed consolidated financial statements of the Company. The Company is not currently able to estimate the possible loss or range of loss until developments in such matters have provided sufficient information to support such an assessment, including quantification of a damage demand from plaintiffs, discovery from other parties and investigation of factual allegations, rulings by courts on motions or appeals, analysis by experts or the status of any settlement negotiations.
In connection with these matters, the Company has incurred and may continue to incur legal expenses, which are expensed as incurred and presented net of any insurance reimbursements. These expenses are recorded in Professional Fees and Other Expenses in the Condensed Consolidated Statements of Operations.
There were no material developments to the legal proceedings previously disclosed in Note 14. “Commitments and Contingencies—Contingencies, Litigation” in the “Notes to Consolidated Financial Statements”
19
PJT Partners Inc.
Notes to Condensed Consolidated Financial Statements – Continued (Unaudited)
(All Dollars Are in Thousands, Except Share and Per Share Data, Except Where Noted)
in “Part II. Item 8. Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.
Guarantee
The Company provides a guarantee to a lending institution for certain loans held by employees for investment in funds of its former Parent, which are secured by the underlying investments in those funds. As of June 30, 2025 and December 31, 2024, the amount guaranteed was $
Indemnifications
The Company has entered and may continue to enter into contracts that contain a variety of indemnification obligations. The Company’s maximum exposure under these arrangements is not known; however, the Company currently expects any associated risk of loss to be insignificant. In connection with these matters, the Company has incurred and may continue to incur legal expenses, which are expensed as incurred.
Transactions and Agreements with former Parent
Employee Matters Agreement
Pursuant to the Employee Matters Agreement, the Company has agreed to pay former Parent the net realized cash benefit resulting from certain compensation-related tax deductions. Amounts are payable annually (for periods in which a cash benefit is realized) within nine months of the end of the relevant tax period. As of June 30, 2025 and December 31, 2024, the Company had accrued $
Certain subsidiaries of the Company are subject to various regulatory requirements in the United States, United Kingdom, Hong Kong, Spain, Japan, United Arab Emirates and the Kingdom of Saudi Arabia, which specify, among other requirements, capital adequacy requirements.
PJT Partners LP is a registered broker-dealer through which advisory and placement services are conducted in the U.S. and is subject to the net capital requirements of Rule 15c3-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). As of June 30, 2025 and December 31, 2024, PJT Partners LP had net capital of $
As of June 30, 2025 and December 31, 2024, PJT Partners (UK) Limited, PJT Partners (HK) Limited, PJT Partners Park Hill (Spain) A.V., S.A.U., PJT Partners Japan K.K., deNovo DIFC, and deNovo Partners Finance were in compliance with local capital adequacy requirements.
20
PJT Partners Inc.
Notes to Condensed Consolidated Financial Statements – Continued (Unaudited)
(All Dollars Are in Thousands, Except Share and Per Share Data, Except Where Noted)
The Company’s activities providing advisory and placement services constitute a single reportable segment. An operating segment is a component of an entity that conducts business and incurs revenues and expenses for which discrete financial information is available that is reviewed by the chief operating decision maker ("CODM") in assessing performance and making resource allocation decisions.
The Company is organized as one operating segment in order to maximize the value of advice to clients by drawing upon the diversified expertise and broad relationships of senior professionals across the Company. The accounting policies of the reportable segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance and allocates resources on a consolidated basis based on consolidated Net Income that is presented on the Condensed Consolidated Statements of Operations as well as other broad considerations, including the market opportunity, available expertise across the Company and the strength and efficacy of professionals’ collaboration. The measure of segment assets is presented on the Condensed Consolidated Statements of Financial Condition as total consolidated assets. The CODM reviews segment assets at the same level or category as presented on the Condensed Consolidated Statements of Financial Condition. The CODM uses consolidated Net Income to assist in assessing performance, establishing compensation, and setting capital priorities including such actions as reinvesting profits into the business, offset dilution or pay dividends. The CODM is regularly provided with the consolidated expenses as presented on the Condensed Consolidated Statements of Operations.
Since the financial markets are global in nature, the Company generally manages its business based on the operating results of the Company taken as a whole, not by geographic region.
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Revenues from Contracts with Customers |
|
|
|
|
|
|
|
|
|
|
|
|
||||
United States |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
United Kingdom |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other International |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total Revenues from Contracts with Customers |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest Income and Other1 |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total Revenues |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
|
June 30, |
|
|
December 31, |
|
||
Assets |
|
|
|
|
|
|
||
United States |
|
$ |
|
|
$ |
|
||
United Kingdom |
|
|
|
|
|
|
||
Other International |
|
|
|
|
|
|
||
Total |
|
$ |
|
|
$ |
|
1
21
PJT Partners Inc.
Notes to Condensed Consolidated Financial Statements – Continued (Unaudited)
(All Dollars Are in Thousands, Except Share and Per Share Data, Except Where Noted)
On July 30, 2025, the Board appointed Peter L.S. Currie as a director of the Company, effective as of July 30, 2025.
The Company has evaluated the impact of subsequent events through the date these financial statements were issued and determined there were no subsequent events requiring adjustment or further disclosure to the financial statements besides the exchange of Partnership Units described in Note 12. “Transactions with Related Parties—Exchange Agreement”.
22
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis should be read in conjunction with PJT Partners Inc.’s Condensed Consolidated Financial Statements and the related notes included in this Quarterly Report on Form 10-Q.
Our Business
PJT Partners is a premier, global, advisory-focused investment bank that was built from the ground up to be different. Our highly experienced, collaborative teams provide independent advice coupled with old-world, high-touch client service. This ethos has allowed us to attract some of the very best talent in the markets in which we operate. We deliver leading advice to many of the world's most consequential companies, effect some of the most transformative transactions and restructurings and raise billions of dollars of capital around the globe to support startups and more established companies.
For further information regarding our business, refer to “Part I. Item 1. Business” in our Annual Report on Form 10-K for the year ended December 31, 2024.
Business Environment
Economic and global financial conditions can materially affect our operational and financial performance. See “Part I. Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 for a discussion of some of the factors that can affect our performance.
Mergers and acquisitions (“M&A”) is a cyclical business that is impacted by macroeconomic conditions. There are several factors influencing global M&A activity in the intermediate term, including monetary policy, global trade policies, greater economic and geopolitical uncertainty and global growth. How these macroeconomic factors impact the strength of strategic activity in the intermediate term is still uncertain and while there are indications of a pickup in M&A activity, the data continues to present a mixed picture. In the second quarter of 2025, worldwide M&A announced volumes increased 33% compared with prior year, however, the number of transactions declined1. While we expect the markets to recover to historical relationships between M&A activity and broader market benchmarks, the pace of such recovery remains unclear.
Global restructuring and special situations trends remained elevated during the second quarter of 2025 due to liability management, balance sheet restructuring and bankruptcy activity. A number of factors continue to drive elevated levels of restructuring, as both corporates and financial sponsors deal with capital markets volatility, challenged business models, and changing consumer preferences. Activity during the second quarter of 2025 remains dispersed across corporates, creditors and financial sponsors as well as a broad cross section of industries and geographies, demonstrating a continued multi-year cycle of elevated activity.
Fund placement activity remains challenging given the global macroeconomic environment, volatility in the market, an overall slowdown in realizations and the supply of alternative investment opportunities in the market seeking capital. Additionally, limited partners have become more discerning in their deployment of capital for both existing and new fund manager relationships. Investors continue to focus on existing relationships and, as a result, the bar for fund managers to attract new investors remains high as a flight to quality persists. As it relates to private capital solutions, the demand for alternative liquidity vehicles from general partners and limited partners continues to be a driver for increased market volumes, and, despite recent market volatility we expect the environment to remain favorable in the intermediate term.
___________________________________________________________________________________________________________________________________________
1Source: LSEG Global Mergers & Acquisitions Review for First Half of 2025 as of June 30, 2025.
23
Key Financial Measures
Revenues
Substantially all of our revenues are derived from contracts with clients to provide advisory and placement services. This revenue is primarily a function of the number of active engagements we have, the size and the complexity of each of those engagements and the fees we charge for our services.
We provide a range of strategic advisory, shareholder advisory, capital markets advisory, and restructuring and special situations services to corporations, financial sponsors, institutional investors and governments around the world. In conjunction with providing restructuring advice, we may also assist with raising various forms of financing, including debt and equity. Our private capital solutions services include providing general partner solutions and investing solutions to clients seeking portfolio liquidity, unfunded commitment relief and investments in secondary markets. Our fund placement services primarily serve a diverse range of investment strategies, including private equity, alternative credit/hedge funds, and real estate. We advise on all aspects of the fundraising process including competitive positioning and market assessment, marketing materials and related documentation including partnership terms and conditions most prevalent in the current environment. We also provide public and private placement fundraising services to our corporate clients.
The amount and timing of the fees paid vary by the type of engagement and are typically based on retainers, completion of a transaction or a capital raise. Fees earned for services provided to alternative asset managers are typically recognized upon acceptance by a fund of capital or capital commitments (referred to as a “closing”), in accordance with terms set forth in individual agreements. For commitment based fees, revenue is recognized over time as commitments are accepted. Fees for such closed-end fund arrangements are generally paid in installments over three or four years and interest is charged to the outstanding balance at an agreed upon rate, such as the Secured Overnight Financing Rate or an alternate reference rate, plus a market-based margin. For funds with multiple closings, the constraint on variable consideration is lifted upon each closing. For open-end fund structures, placement fees are typically calculated as a percentage of a placed investor’s month-end net asset value. Typically, we earn fees for such open-end fund structures over a four year period. For these arrangements, revenue is recognized over time as the constraint over variable consideration is lifted. Placement and underwriting fees earned for public and private placement fundraising services are recognized based on successful completion of the transaction. We may receive non-refundable up-front fees in our contracts with customers, which are recorded as revenues in the period over which services are estimated to be provided.
A transaction can fail to be completed for many reasons, including global and/or regional economic conditions, failure of parties to agree upon final terms, to secure necessary board or shareholder approvals, to secure necessary financing or to achieve necessary regulatory approvals. In the case of bankruptcy engagements, fees are subject to approval of the court.
Interest Income and Other – Interest Income and Other represents interest typically earned on Cash and Cash Equivalents, investments in Treasury securities and outstanding placement fees receivable; foreign exchange gains and losses arising from transactions denominated in currencies other than U.S. dollars; sublease income; the amount of expense reimbursement invoiced to clients related to out-of-pocket expenses; and the mark-to-market impact on fair value of certain equity securities received in exchange for advisory services. Interest on placement fees receivable is earned from the time revenue is recognized and is calculated as mutually agreed upon with the receivable counterparty. Interest receivable is included in Accounts Receivable, Net in the Condensed Consolidated Statements of Financial Condition.
Expenses
Compensation and Benefits – Compensation and Benefits expense includes salaries, restricted and unrestricted cash awards, benefits, employer taxes and equity-based compensation associated with the grants of equity-based awards. Changes in this expense are driven by fluctuations in the number of employees, the composition of our workforce, business performance, compensation adjustments in relation to market movements, changes in rates for employer taxes and other cost increases affecting benefit plans. The expense associated with our restricted and unrestricted cash award and equity plans can also have a significant impact and may vary from year to year. Certain awards are expensed over the requisite service period for partners and employees who are or will become retirement
24
eligible prior to the stated vesting date. Over time, a greater number of partners and employees may become retirement eligible and the related requisite service period over which the expense is recognized will be shorter than the stated vesting period.
We maintain compensation programs, including salaries, annual incentive compensation (that may include components of unrestricted cash, restricted cash and/or equity-based awards) and benefits programs. We manage compensation to estimates of competitive levels based on market conditions and performance. Our compensation expense reflects our objective to retain key personnel by maintaining competitive compensation levels. It also reflects the impact of newly-hired senior professionals, including any related grants of equity awards.
Increasing the number of high-caliber, experienced senior level employees is critical to our growth efforts and our continued investment in senior talent may also increase compensation and benefits expense. These hires generally do not generate significant revenue in the year they are hired.
Non-Compensation Expense – Non-Compensation expenses are the other costs typical to operating our business, which generally consist of Occupancy and Related, Travel and Related, Professional Fees, Communications and Information Services, Depreciation and Amortization, and Other Expenses. Further information regarding these expenses can be found in “Part II. Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2024.
Income Taxes – PJT Partners Inc. is a corporation subject to U.S. federal, state and local income taxes in jurisdictions where it does business. Our businesses generally operate as partnerships for U.S. federal and state purposes and as corporate entities in non-U.S. jurisdictions. In the U.S. federal and state jurisdictions, taxes related to income earned by these entities generally represent obligations of the individual members and partners.
Our operating entities are generally subject to New York City Unincorporated Business Tax and to entity-level income taxes imposed by state and local as well as non-U.S. jurisdictions, as applicable. These taxes have been reflected in our condensed consolidated financial statements.
PJT Partners Inc. is subject to U.S. federal, state and local corporate income tax on its allocable share of results of operations from the holding partnership (PJT Partners Holdings LP).
On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”), which includes a broad range of tax reform provisions, was signed into law in the United States. We are continuing to assess the impact of OBBBA and does not expect it to have a material impact on the Company’s 2025 condensed consolidated financial statements.
Non-Controlling Interests
PJT Partners Inc. is a holding company and its only material asset is its controlling equity interest in PJT Partners Holdings LP, a holding partnership that holds the Company's operating subsidiaries, and certain cash and cash equivalents it may hold from time to time. As the sole general partner of PJT Partners Holdings LP, PJT Partners Inc. operates and controls all of the business and affairs and consolidates the financial results of PJT Partners Holdings LP and its operating subsidiaries. The portion of net income attributable to the non-controlling interests is presented separately in the Condensed Consolidated Statements of Operations.
25
Condensed Consolidated Results of Operations
The following table sets forth our condensed consolidated results of operations for the three and six months ended June 30, 2025 and 2024:
|
|
Three Months Ended |
|
|
|
|
|
Six Months Ended |
|
|
|
|
||||||||||||
|
|
2025 |
|
|
2024 |
|
|
Change |
|
|
2025 |
|
|
2024 |
|
|
Change |
|
||||||
|
|
(Dollars in Thousands) |
|
|||||||||||||||||||||
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Advisory Fees |
|
$ |
354,521 |
|
|
$ |
307,082 |
|
|
|
15 |
% |
|
$ |
636,708 |
|
|
$ |
595,763 |
|
|
|
7 |
% |
Placement Fees |
|
|
43,219 |
|
|
|
46,873 |
|
|
|
(8 |
)% |
|
|
79,250 |
|
|
|
81,362 |
|
|
|
(3 |
)% |
Interest Income and Other |
|
|
9,144 |
|
|
|
6,226 |
|
|
|
47 |
% |
|
|
15,457 |
|
|
|
12,449 |
|
|
|
24 |
% |
Total Revenues |
|
|
406,884 |
|
|
|
360,181 |
|
|
|
13 |
% |
|
|
731,415 |
|
|
|
689,574 |
|
|
|
6 |
% |
Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Compensation and Benefits |
|
|
276,834 |
|
|
|
250,326 |
|
|
|
11 |
% |
|
|
497,976 |
|
|
|
479,254 |
|
|
|
4 |
% |
Occupancy and Related |
|
|
14,865 |
|
|
|
12,107 |
|
|
|
23 |
% |
|
|
28,773 |
|
|
|
24,268 |
|
|
|
19 |
% |
Travel and Related |
|
|
11,445 |
|
|
|
9,055 |
|
|
|
26 |
% |
|
|
22,608 |
|
|
|
18,156 |
|
|
|
25 |
% |
Professional Fees |
|
|
9,065 |
|
|
|
8,780 |
|
|
|
3 |
% |
|
|
16,436 |
|
|
|
17,129 |
|
|
|
(4 |
)% |
Communications and |
|
|
9,716 |
|
|
|
8,577 |
|
|
|
13 |
% |
|
|
18,876 |
|
|
|
16,437 |
|
|
|
15 |
% |
Depreciation and |
|
|
3,282 |
|
|
|
3,112 |
|
|
|
5 |
% |
|
|
6,494 |
|
|
|
6,610 |
|
|
|
(2 |
)% |
Other Expenses(1) |
|
|
5,198 |
|
|
|
3,825 |
|
|
|
36 |
% |
|
|
11,195 |
|
|
|
9,418 |
|
|
|
19 |
% |
Total Expenses |
|
|
330,405 |
|
|
|
295,782 |
|
|
|
12 |
% |
|
|
602,358 |
|
|
|
571,272 |
|
|
|
5 |
% |
Income Before Provision |
|
|
76,479 |
|
|
|
64,399 |
|
|
|
19 |
% |
|
|
129,057 |
|
|
|
118,302 |
|
|
|
9 |
% |
Provision (Benefit) for Taxes |
|
|
15,041 |
|
|
|
11,368 |
|
|
|
32 |
% |
|
|
(6,544 |
) |
|
|
11,899 |
|
|
N/M |
|
|
Net Income |
|
|
61,438 |
|
|
|
53,031 |
|
|
|
16 |
% |
|
|
135,601 |
|
|
|
106,403 |
|
|
|
27 |
% |
Net Income Attributable |
|
|
28,538 |
|
|
|
24,715 |
|
|
|
15 |
% |
|
|
48,685 |
|
|
|
45,464 |
|
|
|
7 |
% |
Net Income Attributable to |
|
$ |
32,900 |
|
|
$ |
28,316 |
|
|
|
16 |
% |
|
$ |
86,916 |
|
|
$ |
60,939 |
|
|
|
43 |
% |
N/M Not meaningful.
(1) Certain balances on the Condensed Consolidated Statements of Operations in the prior period have been reclassified to conform to their current presentation. For the three and six months ended June 30, 2024, this resulted in a reclassification of $3.3 million and $6.4 million respectively, from Other Expenses to Communications and Information Services. This reclassification had no impact on net income or Condensed Consolidated Statements of Financial Condition.
Revenues
The following table provides revenue statistics for the three and six months ended June 30, 2025 and 2024:
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Total Number of Clients |
|
|
233 |
|
|
|
236 |
|
|
|
294 |
|
|
|
293 |
|
Total Number of Fees of at least $1 Million from |
|
|
72 |
|
|
|
70 |
|
|
|
133 |
|
|
|
128 |
|
Total Revenues were $406.9 million for the three months ended June 30, 2025, an increase of $46.7 million compared with $360.2 million for the three months ended June 30, 2024. Advisory Fees were $354.5 million for the three months ended June 30, 2025, an increase of $47.4 million compared with $307.1 million for the three months ended June 30, 2024. The increase in Advisory Fees was principally due to an increase in strategic advisory revenues. Placement Fees were $43.2 million for the three months ended June 30, 2025, a decrease of $3.7 million
26
compared with $46.9 million for the three months ended June 30, 2024. The decrease in Placement Fees was due to a decrease in fund placement revenues. Interest Income and Other was $9.1 million for the three months ended June 30, 2025, an increase of $2.9 million compared with $6.2 million for the three months ended June 30, 2024. The increase in Interest Income and Other was principally due to an increase in the fair market value of certain equity securities received as part of transaction compensation.
Total Revenues were $731.4 million for the six months ended June 30, 2025, an increase of $41.8 million compared with $689.6 million for the six months ended June 30, 2024. Advisory Fees were $636.7 million for the six months ended June 30, 2025, an increase of $40.9 million compared with $595.8 million for the six months ended June 30, 2024. The increase in Advisory Fees was principally due to an increase in strategic advisory revenues. Placement Fees were $79.3 million for the six months ended June 30, 2025, a decrease of $2.1 million compared with $81.4 million for the six months ended June 30, 2024. The decrease in Placement Fees was due to a decrease in fund placement revenues. Interest Income and Other was $15.5 million for the six months ended June 30, 2025, an increase of $3.0 million compared with $12.4 million for the six months ended June 30, 2024. The increase in Interest Income and Other was principally due to an increase in the fair market value of certain equity securities received as part of transaction compensation.
Expenses
Expenses were $330.4 million for the three months ended June 30, 2025, an increase of $34.6 million compared with $295.8 million for the three months ended June 30, 2024. The increase in expenses was principally due to increases in Compensation and Benefits, Occupancy and Related and Travel and Related of $26.5 million, $2.8 million and $2.4 million, respectively. The increase in Compensation and Benefits Expense was driven by higher revenues compared with prior year, partially offset by a lower accrual rate. Occupancy and Related increased principally due to the expansion of our London and New York offices. Travel and Related increased principally due to increased business development activity and higher cost of travel.
Expenses were $602.4 million for the six months ended June 30, 2025, an increase of $31.1 million compared with $571.3 million for the six months ended June 30, 2024. The increase in expenses was principally due to increases in Compensation and Benefits, Occupancy and Related and Travel and Related of $18.7 million, $4.5 million and $4.5 million, respectively. The increase in Compensation and Benefits Expense was driven by higher revenues compared with prior year, partially offset by a lower accrual rate. Occupancy and Related increased principally due to the expansion of our London and New York offices. Travel and Related increased principally due to increased business development activity and higher cost of travel.
Provision (Benefit) for Taxes
The Company’s Provision for Taxes for the three months ended June 30, 2025 was $15.0 million, which represents an effective tax rate of 19.7% on pretax income of $76.5 million. The Company’s Provision for Taxes for the three months ended June 30, 2024 was $11.4 million, which represents an effective tax rate of 17.7% on pretax income of $64.4 million.
The Company’s Benefit for Taxes for the six months ended June 30, 2025 was $6.5 million, which represents an effective tax rate of -5.1% on pretax income of $129.1 million. The Company’s Provision for Taxes for the six months ended June 30, 2024 was $11.9 million, which represents an effective tax rate of 10.1% on pretax income of $118.3 million.
Non-Controlling Interests
Net Income Attributable to Non-Controlling Interests is calculated by multiplying the Income Before Provision (Benefit) for Taxes by the percentage allocation of the income between the holders of common units of partnership interest in PJT Partners Holdings LP (“Partnership Units”) and holders of PJT Partners Inc. Class A common stock after considering any contractual arrangements that govern the allocation of income.
27
Liquidity and Capital Resources
General
We regularly monitor our liquidity position, including cash and cash equivalents, investments, working capital assets and liabilities, any commitments and other liquidity requirements.
Our assets have been historically comprised of cash and cash equivalents, investments, receivables arising from advisory and placement engagements and operating lease right-of-use assets. Our liabilities generally include accrued compensation and benefits, accounts payable and accrued expenses, taxes payable and operating lease liabilities. We expect to pay a significant amount of incentive compensation toward the end of each year and during the beginning of the next calendar year with respect to the prior year’s results. A portion of annual compensation may be awarded with equity-based compensation and thus requires less cash. We expect levels of cash to decline at the end of the year and during the first quarter of each year after incentive compensation is paid to our employees. We then expect cash to build throughout the remainder of the year.
On July 29, 2024, PJT Partners Holdings LP, as borrower the ("Borrower"), entered into a syndicated revolving credit agreement (the “Credit Agreement”) and related documents with Bank of America, N.A., as the administrative agent (the “Administrative Agent”), and certain other financial institutions party thereto as lenders. The Credit Agreement provides for a revolving credit facility with aggregate principal amount of up to $100 million. Further information regarding the Credit Agreement can be found in Note 13. “Commitments and Contingencies—Commitments, Line of Credit” in the “Notes to Condensed Consolidated Financial Statements” in “—Item 1. Financial Statements” of this filing. As of June 30, 2025 and December 31, 2024, we were in compliance with the debt covenants under the Credit Agreement. Additionally, as of June 30, 2025 and December 31, 2024, there were no borrowings outstanding under the Credit Agreement.
We evaluate our cash needs on a regular basis. As of June 30, 2025 and December 31, 2024, we had cash, cash equivalents and short-term investments of $318.4 million and $546.8 million, respectively. The vast majority of these balances are either held in institutions labeled by the Financial Stability Board as global systemically important banks, money market funds or Treasury securities. Although we maintain multiple banking relationships with both global and regional banks and actively monitor the financial stability of such institutions, a failure at any institution where we maintain a banking relationship could impact our liquidity.
Our liquidity is highly dependent upon cash receipts from clients, which are generally tied to the successful completion of transactions and the timing of receivable collections. As of June 30, 2025 and December 31, 2024, total accounts receivable, net of allowance for credit losses, was $359.0 million and $320.8 million, respectively. As of June 30, 2025 and December 31, 2024, the allowance for credit losses was $5.2 million and $2.5 million, respectively. Included in Accounts Receivable, Net are long-term receivables of $98.6 million and $88.6 million as of June 30, 2025 and December 31, 2024, respectively, related to placement fees that are generally paid in installments over a period of three to four years.
Sources and Uses of Liquidity
Our primary cash needs are for working capital, paying operating expenses including cash compensation to our employees, exchanging of Partnership Units for cash, repurchasing shares of the Company’s Class A common stock, paying income taxes, dividend payments, partnership tax distributions, capital expenditures, making payments pursuant to the tax receivable agreement, commitments and strategic investments. We expect to fund these liquidity requirements through cash flows from operations and borrowings under our revolving credit facility. Our ability to fund these needs will depend, in part, on our ability to generate or raise cash in the future which depends on our future financial results, which are subject to general economic, financial, competitive, legislative and regulatory factors.
Additionally, our ability to generate positive cash flow from operations will be impacted by global economic conditions. If our cash flows from operations are significantly reduced, we may need to borrow from our revolving credit facility, incur debt, or issue additional equity. Although we believe that our revolving credit facility, and our ability to renew it, will permit us to finance our operations on acceptable terms and conditions for the foreseeable future, our access to, and the availability of, financing on acceptable terms and conditions in the future will be
28
impacted by many factors, including: business performance; our credit ratings or absence of a credit rating; the liquidity of the overall capital markets; the current state of the economy; and stability of our lending institution. We cannot provide any assurance that such financing will be available to us on acceptable terms or that such financing will be available at all. We believe that our future cash from operations and availability under our revolving credit facility, together with our access to funds on hand, will provide adequate resources to fund our liquidity and capital needs.
Regulatory Capital
We are subject to regulatory requirements in the U.S. and certain international jurisdictions to ensure general financial soundness and liquidity. This requires, among other things, that we comply with certain minimum capital requirements, recordkeeping, reporting procedures, experience and training requirements for employees and certain other requirements and procedures. These regulatory requirements may restrict the flow of funds to and from affiliates. See Note 14. “Regulated Entities” in the “Notes to Condensed Consolidated Financial Statements” in “—Item 1. Financial Statements” of this filing for further information. The licenses under which we operate are meant to be appropriate to conduct our business. We actively monitor our regulatory capital base and we believe that we provide each of these entities with sufficient capital and liquidity, consistent with their business and regulatory requirements.
Our activities may also be subject to regulation, including regulatory capital requirements, by various other foreign jurisdictions and self-regulatory organizations.
We do not anticipate that compliance with any and all such requirements will materially adversely impact the availability of funds for domestic and parent-level purposes.
Exchange Agreement
Subject to the terms and conditions of the exchange agreement, as amended, between us and certain of the holders of Partnership Units (other than PJT Partners Inc.), holders of Partnership Units have the right, subject to the terms and conditions set forth in the partnership agreement of PJT Partners Holdings LP, on a quarterly basis, to exchange all or part of the Partnership Units. Further, the Company may also require holders of Partnership Units who are not Service Providers (as defined in the Partnership Agreement of PJT Partners Holdings LP) to exchange such Partnership Units. We retain the sole option to determine whether to settle the exchange in either cash or for shares of PJT Partners Inc. Class A common stock on a one-for-one basis. Depending on our liquidity and capital resources, market conditions, the timing and concentration of exchange requests and other considerations, we may choose to fund exchanges of Partnership Units with available cash, borrowings or new issuances of PJT Partners Inc. Class A common stock or to settle exchanges by issuing PJT Partners Inc. Class A common stock to the exchanging holder of Partnership Units.
For the six months ended June 30, 2025 and 2024, certain holders of Partnership Units exchanged 0.5 million and 0.3 million Partnership Units, respectively, for cash in the amounts of $81.3 million and $30.3 million, respectively.
Share Repurchase Program
On February 6, 2024, the Company announced that the Board authorized a $500 million Class A common stock repurchase program, which replaced the then-existing $200 million repurchase program authorized on April 25, 2022. As of June 30, 2025, the Company’s remaining repurchase authorization was $87.2 million. Under the current repurchase program, which has no expiration date, shares of the Company’s Class A common stock may be repurchased from time to time in open market transactions, in privately negotiated transactions or otherwise. The timing and the actual number of shares repurchased depend on a variety of factors, including legal requirements, price, and economic and market conditions. The repurchase program may be suspended or discontinued at any time.
29
During the six months ended June 30, 2025, the Company repurchased 1.3 million shares of the Company’s Class A common stock at an average price per share of $149.85, or $190.5 million in aggregate, excluding excise tax on net share repurchases, pursuant to the share repurchase program.
Contractual Obligations
For a discussion of our contractual obligations, refer to “Part II. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Contractual Obligations” in our Annual Report on Form 10-K for the year ended December 31, 2024. There have not been any material changes to our contractual obligations since December 31, 2024.
Commitments and Contingencies
Litigation
With respect to our litigation matters, including any litigation discussed under the caption “Legal Proceedings” elsewhere in this report, we are not currently able to estimate the possible loss or range of loss until developments in such matters have provided sufficient information to support such an assessment, including, but not limited to, quantification of a damage demand from plaintiffs, discovery from other parties and investigation of factual allegations, rulings by courts on motions or appeals, analysis by experts or the status of any settlement negotiations. While the ultimate outcome and the costs associated with litigation are inherently uncertain and difficult to predict, we believe, based on current knowledge and after consultation with counsel, that we are not currently party to any material pending proceedings, individually or in the aggregate, the resolution of which would have a material effect on the Company.
Guarantee
The Company provides a guarantee to a lending institution for certain loans held by employees for investment in funds of its former Parent, which are secured by the underlying investments in those funds. As of June 30, 2025 and December 31, 2024, the amount guaranteed was $1.7 million and $2.0 million, respectively. In connection with this guarantee, we currently expect any associated risk of loss to be insignificant.
Indemnifications
We have entered and may continue to enter into contracts that contain a variety of indemnification obligations. Our maximum exposure under these arrangements is not known; however, we currently expect any associated risk of loss to be insignificant. In connection with these matters, we have incurred and may continue to incur legal expenses, which are expensed as incurred.
Tax Receivable Agreement
We have entered into a tax receivable agreement with the holders of Partnership Units (other than PJT Partners Inc.) that provides for the payment by PJT Partners Inc. to exchanging holders of Partnership Units of 85% of the benefits, if any, that PJT Partners Inc. is deemed to realize as a result of the increases in tax basis related to such exchanges of Partnership Units and of certain other tax benefits related to entering into the tax receivable agreement, including tax benefits attributable to payments under the tax receivable agreement. As of June 30, 2025 and December 31, 2024, the Company had amounts due of $33.5 million and $29.3 million, respectively, pursuant to the tax receivable agreement, which represent management’s best estimate of the amounts currently expected to be owed in connection with the tax receivable agreement. Actual payments may differ significantly from estimated amounts due.
Further information regarding the tax receivable agreement can be found in “Part II. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2024.
30
Other
See Notes 8, 10, 11 and 13 in the “Notes to Condensed Consolidated Financial Statements” in “—Item 1. Financial Statements” of this filing for further information in connection with income taxes, equity-based and other deferred compensation plans, leasing arrangements and commitments, respectively.
Critical Accounting Estimates
A discussion of critical accounting estimates is included in “Part II. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2024.
Recent Accounting Developments
Information regarding recent accounting developments and their impact on our financial statements can be found in Note 2. “Summary of Significant Accounting Policies” in the “Notes to Condensed Consolidated Financial Statements” in “—Item 1. Financial Statements” of this filing.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Quantitative and qualitative disclosures about market risk can be found in “Part II. Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the year ended December 31, 2024. Our exposures to market risk have not changed materially since December 31, 2024.
ITEM 4. CONTROLS AND PROCEDURES
Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) occurred during our most recent quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
31
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
From time to time, the Company and its affiliates may be subject to legal proceedings and claims in the ordinary course of business. In addition, government agencies and regulatory organizations in countries in which we conduct business undertake periodic examinations and may initiate administrative proceedings regarding the Company’s and its affiliates’ businesses, including, among other matters, accounting, compliance, and operational matters, that can result in censure, fine, the issuance of cease-and-desist orders or the suspension or expulsion of a broker-dealer, or its directors, officers or employees. It is our policy to cooperate fully with such governmental requests, examinations and administrative proceedings. We believe, based on current knowledge and after consultation with counsel, that we are not currently party to any material pending proceedings, individually or in the aggregate, the resolution of which would have a material effect on the Company.
Further disclosure regarding legal proceedings is provided in Note 13. “Commitments and Contingencies—Contingencies, Litigation” in the “Notes to Condensed Consolidated Financial Statements” in “—Item 1. Financial Statements” of this filing.
ITEM 1A. RISK FACTORS
There were no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2024.
The risks described in our Annual Report on Form 10-K for the year ended December 31, 2024 and in our subsequently filed Quarterly Reports on Form 10-Q are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities in the Second Quarter of 2025
|
|
|
|
|
|
|
|
Total Number |
|
|
|
Approximate Dollar |
|||
|
|
|
|
|
|
|
|
of Shares |
|
|
|
Value of Shares |
|||
|
|
|
|
|
|
|
|
Purchased as |
|
|
|
that May Yet Be |
|||
|
|
Total Number |
|
|
|
|
|
Part of Publicly |
|
|
|
Purchased Under |
|||
|
|
of Shares |
|
|
Average Price |
|
|
Announced Plans |
|
|
|
the Plans or |
|||
|
|
Repurchased |
|
|
Paid Per Share |
|
|
or Programs (a) |
|
|
|
Programs (a) |
|||
April 1 to April 30 |
|
|
353,224 |
|
|
$ |
130.74 |
|
|
|
353,224 |
|
|
$ |
104.4 million |
May 1 to May 31 |
|
|
77,594 |
|
|
|
145.95 |
|
|
|
77,594 |
|
|
|
93.0 million |
June 1 to June 30 |
|
|
38,300 |
|
|
|
152.52 |
|
|
|
38,300 |
|
|
|
87.2 million |
Total |
|
|
469,118 |
|
|
$ |
135.04 |
|
|
|
469,118 |
|
|
$ |
87.2 million |
Unregistered Sales/Issuances of Equity Securities and Use of Proceeds
There were no unregistered sales/issuances of equity securities during the second quarter of 2025.
32
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
During the three months ended June 30, 2025,
33
ITEM 6. EXHIBITS
Exhibit Number |
|
Exhibit Description |
|
|
|
2.1 |
|
Separation and Distribution Agreement by and among The Blackstone Group L.P., Blackstone Holdings I L.P., New Advisory GP L.L.C., PJT Partners Inc. and PJT Partners Holdings LP, dated as of October 1, 2015 (incorporated herein by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 5, 2015). |
|
|
|
3.1 |
|
Restated Certificate of Incorporation of PJT Partners Inc. (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on July 28, 2023). |
|
|
|
3.2 |
|
Amended and Restated By-Laws of PJT Partners Inc. (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 5, 2015). |
|
|
|
31.1 |
|
Certification of the Chief Executive Officer pursuant to Rule 13a-14(a). |
|
|
|
31.2 |
|
Certification of the Chief Financial Officer pursuant to Rule 13a-14(a). |
|
|
|
32.1 |
|
Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith). |
|
|
|
32.2 |
|
Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith). |
|
|
|
101.INS |
|
Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because iXBRL tags are embedded within the Inline XBRL document. |
|
|
|
101.SCH |
|
Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents. |
|
|
|
104 |
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
The agreements and other documents filed as exhibits to this report are not intended to provide factual information or other disclosure other than with respect to the terms of the agreements or other documents themselves, and you should not rely on them for that purpose. In particular, any representations and warranties made by us in these agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs as of the date they were made or at any other time.
34
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: July 31, 2025 |
|
|
|
|
|
|
|
|
|
PJT Partners Inc. |
|
|
|
|
|
|
|
By: |
/s/ Paul J. Taubman |
|
|
Name: |
Paul J. Taubman |
|
|
Title: |
Chief Executive Officer |
|
|
|
|
|
|
By: |
/s/ Helen T. Meates |
|
|
Name: |
Helen T. Meates |
|
|
Title: |
Chief Financial Officer |
|
|
|
(Principal Financial and Accounting Officer) |
35